Interaction Checker

Interacciones de Exemestano

Exemestano (Aromasin), inhibidor de la aromatasa, tiene 61 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 16; moderadas: 33; leves: 12; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (16)

  • Desogestrel y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • EstradiolestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Estradiol y dienogestanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Estradiol y noretisteronaestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Estrógenos conjugadosestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Estrógenos conjugados y bazedoxifenoestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Estrógenos esterificados y metiltestosteronaestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Etonogestrel y etinilestradiolestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • FulvestrantestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Levonorgestrel y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Norelgestromina y etinilestradiolestrógenoGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Noretisterona y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Norgestimato y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • Norgestrel y etinilestradiolanticonceptivo oralGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

Interacciones moderadas (33)

  • Aprepitantinhibidor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • ClobazambenzodiazepinaModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • DexametasonacorticosteroideModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • EfavirenzantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • EtravirinaantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • NevirapinaantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • RifabutinaantibióticoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Moderada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1 IES 027 BMD Exemestane N=29 Tamoxifen 1 N=38 Exemestane N=59 Placebo 1 N=65 Lumbar spine (%) -3.1 -0.2 -3.5 -2.4 Femoral neck (%) -4.2 -0.3 -4.6 -2.6 During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally… (etiqueta de Exemestano, Advertencias y precauciones)

  • TopiramatoanticonvulsivoModerada

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

Menciones leves (12)

  • Ácido zoledrónicobisfosfonatoLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

  • AlendronatobisfosfonatoLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

  • Calcipotriolanálogo de la vitamina DLeve

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (etiqueta de Exemestano, Advertencias y precauciones)

  • Calcitriolanálogo de la vitamina DLeve

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (etiqueta de Exemestano, Advertencias y precauciones)

  • Doxercalciferolanálogo de la vitamina DLeve

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (etiqueta de Exemestano, Advertencias y precauciones)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoLeve

    Drugs That Induce CYP 3A4 Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. (etiqueta de Exemestano, Interacciones medicamentosas)

  • IbandronatobisfosfonatoLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

  • MegestrolprogestágenoLeve

    In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with EXEMESTANE and in 1.8% of patients treated with megestrol acetate. (etiqueta de Exemestano, Advertencias y precauciones)

  • PamidronatobisfosfonatoLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

  • Paricalcitolanálogo de la vitamina DLeve

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (etiqueta de Exemestano, Advertencias y precauciones)

  • RisedronatobisfosfonatoLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

  • Vitamina DVitaminas y mineralesLeve

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (etiqueta de Exemestano, Advertencias y precauciones)

Compruebe Exemestano frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.